Pathogenic Antibodies and (Rapidly Progressive) Dementia syndromes

Pathogenic Antibodies and (Rapidly Progressive) Dementia syndromes - PARADE study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47904

Enrollment

300

Registered

2019-03-20

Start date

2019-05-28

Completion date

Unknown

Last updated

2024-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

autoimmune encephalitis inflamed brain

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Patients aged >= 18 years - Patients who have given written informed consent - patients with a clinical profile that fits one the described groups (rapidly progressive dementia of atypical dementia syndromes)

Exclusion criteria

Exclusion criteria: - Age below 18 years - Patient objects after initial informed consent - Patient with mild cognitive impairment (MCI), subjective memory complaints or vascular dementia

Design outcomes

Primary

Measure	Time frame
1) The characterization of (new) antibody-related dementia syndromes. 2) The frequency of the antibody-mediated dementia syndromes. 3) Outcome of autoimmune dementia.	—

Secondary

Measure	Time frame
1. What clinical and epidemiological markers are linked to the specific, individual antibodies? 2. What markers define poor or good prognosis?	—

Countries

Netherlands

Outcome results